Form 4: ADPT CFO Sells Shares After Option Exercises

Adaptive Biotechnologies CFO Kyle Piskel exercised stock options and subsequently sold a significant number of common shares under a pre-arranged 10b5-1 trading plan.

Summary

• Kyle Piskel, Chief Financial Officer of Adaptive Biotechnologies Corp (ADPT), engaged in transactions on November 28, 2025.
• Piskel exercised stock options to acquire a total of 110,114 shares of common stock.
• These exercises included 11,980 shares at an exercise price of $6.55, 3,750 shares at $7.80, and 94,384 shares at $12.14.
• Following the option exercises, Piskel sold 162,820 shares of common stock at a weighted-average price of $19.50 per share.
• The sales occurred in a price range from $19.28 to $19.72.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2025.
• After these transactions, Piskel directly beneficially owns 216,637 shares of common stock and 8,581 unexercised stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a large insider sale can sometimes be viewed negatively, the execution under a 10b5-1 plan mitigates concerns about opportunistic selling. The CFO also realized significant gains by exercising options at much lower prices, which is a positive for the individual.

Positives

• The CFO exercised options at significantly lower prices ($6.55, $7.80, $12.14) compared to the sale price ($19.50), indicating a profitable transaction for the insider.
• The transactions were executed under a Rule 10b5-1 trading plan, which suggests pre-planned activity and reduces concerns about opportunistic insider trading.

Negatives

• A significant sale of 162,820 shares by a Chief Financial Officer could be interpreted by some investors as a lack of confidence in the company's near-term stock price performance, despite being part of a 10b5-1 plan.

Future Outlook

NA

Industry Context

This Form 4 filing details an insider transaction, which is specific to the individual and company, and does not directly reflect broader industry trends. However, insider selling, even under a 10b5-1 plan, is often scrutinized by investors in the biotechnology sector for potential signals about future company performance or valuation.

Related Party Transactions

• The transactions involve the Chief Financial Officer of Adaptive Biotechnologies Corp exercising stock options and selling company shares, which are inherently related-party transactions as defined by SEC regulations for insider reporting.

Stakeholder Impact

• Shareholders may interpret the significant insider sale as a potential signal regarding the company's valuation or future prospects, although the 10b5-1 plan mitigates immediate concerns.
• Employees are not directly impacted by this specific transaction, but general market perception of insider activity can indirectly influence morale or confidence.

Key Dates

Recommendation

The filing details a pre-planned insider transaction by the CFO, involving the exercise of options and subsequent sale of shares. While the sale is substantial, its execution under a 10b5-1 plan suggests a personal financial planning event rather than a signal of deteriorating company fundamentals. The CFO still retains a significant number of shares and some unexercised options. Without additional company-specific news or financial performance data, this transaction alone does not warrant a change from a 'hold' position, as it's a routine insider activity for liquidity or diversification.

Keywords

Adaptive Biotechnologies, ADPT, Form 4, Insider Trading, Stock Options, CFO, Kyle Piskel, 10b5-1 Plan, Share Sale, Beneficial Ownership